Track BioAge Labs, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

BioAge Labs, Inc. BIOA · Stock Open BioAge Labs, Inc. in new tab

5.95 USD
P/E
1.38
EPS
-2.39
P/B
0.72
ROE
-28.21
Beta
1.08
Target Price
32.56 USD
Loading chart...
Key Metrics
Earnings dateNov. 5, 2026
P/E1.38
EPS-2.39
Book Value8.19
Price to Book0.72
Debt/Equity0.76
% Insiders2.361%
Growth
Revenue Growth0.02%
Estimates
Forward P/E-2.35
Forward EPS-2.50
Target Mean Price32.56

DCF valuation

Model fair value for BioAge Labs, Inc. (BIOA)
Result
Sign in to run the valuation for BIOA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Buy · mean target 32.56 USD (low 8.00, high 73.00) · as of 2 Nov 2026
Low 8.00
Mean 32.56
High 73.00
Price 5.95
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

BioAge Labs, Inc. Logo BioAge Labs, Inc. Analysis (BIOA)

Is BioAge Labs, Inc. a good investment? BioAge Labs, Inc. (BIOA) is currently trading at 5.95 USD. Market analysts have a consensus price target of 32.56 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 1.38. This relatively low multiple may signal that BioAge Labs, Inc. is undervalued compared to historical market norms.

Earnings Schedule: BioAge Labs, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -2.50.

Investor FAQ

Does BioAge Labs, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is BioAge Labs, Inc.?

BioAge Labs, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -2.39.

Company Profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Exchange Ticker
BIOA
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion